Table 3.

Efficacy of TASIT compared to SPT on survival without LT, change in PT%, and change in serum ALT value in patients with ALF using multivariate regression analysis.

	Survival without LT			PT%			ALT
	OR	95% CI	P value	OR	95% CI	P value	OR	95% CI	P value
All population
TASIT	1.42	0.45–4.42	.54	18.23	8.00 to 28.45	<.001	−0.09	−0.33 to 0.14	.44
Anticoagulation	0.93	0.25–3.16	.91	−3.90	−16.29 to 8.49	.53	−0.40	−0.69 to −0.12	.01
With coma	0.15	0.05–0.40	<.001	−25.96	−38.28 to −13.64	<.001	−0.06	−0.34 to 0.23	.69
Sex (female)	0.49	0.17–1.38	.18	−3.48	−13.23 to 6.27	.48	0.07	−0.15 to 0.29	.54
Age (every 10 yr)	0.67	0.46–0.94	.03	−2.18	−4.94 to 0.58	.12	0.02	−0.05 to 0.08	.60
High-LDH subgroup
TASIT	3.61	0.25–51.72	.33	10.21	−13.88 to 34.31	.40	−0.15	−0.77 to 0.47	.63
Anticoagulation	0.00	NA	1.00	4.17	−17.21 to 25.54	.70	−0.45	−0.99 to 0.10	.11
With coma	0.06	0.01–0.32	<.001	−37.77	−58.26 to −17.28	<.001	0.15	−0.38 to 0.67	.58
Sex (female)	1.28	0.23–8.68	.78	−3.50	−18.09 to 11.09	.63	0.23	−0.13 to 0.60	.21
Age (every 10 yr)	0.99	0.49–1.97	.98	0.09	−4.46 to 4.64	.97	0.03	−0.09 to 0.14	.66
Low-LDH subgroup
TASIT	0.29	0.05–1.44	.14	12.71	−3.28 to 28.70	.12	−0.12	−0.43 to 0.19	.45
Anticoagulation	2.90	0.56–16.25	.21	−6.55	−22.58 to 9.47	.41	−0.38	−0.69 to −0.17	.02
With coma	0.28	0.06–1.25	.10	−18.34	−35.57 to −1.11	.04	−0.23	−0.56 to 0.11	.17
Sex (female)	0.17	0.03–0.70	.02	−4.60	−18.91 to 9.71	.52	−0.11	−0.39 to 0.17	.42
Age (every 10 yr)	0.62	0.36–0.97	.05	−3.14	−6.82 to 0.55	.69	0.01	−0.06 to 0.08	.78

ALF = acute liver failure, ALT = alanine aminotransferase, CI = confidence interval, LT = liver transplantation, LDH = lactate dehydrogenase, OR = odds ratio, PT% = prothrombin activity percentage, TASIT = transcatheter arterial steroid injection therapy, SPT = systemic steroid pulse therapy.